Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation	Hematopoietic and Lymphatic System Neoplasm	Recruiting	Phase 1	2026-09-22		NCT07025538

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
City of Hope Medical Center	347
National Cancer Institute (NCI)	3015

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
City of Hope Medical Center	Duarte	United States	313

Clinical trials